AveXis Inc (AVXS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Sean P. Nolan
Employees:
10,200
2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN, IL 60015
972-725-7797

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.

Data derived from most recent annual or quarterly report
Market Cap 8.02 Billion Shares Outstanding36.816 Million Avg 30-day Volume 988.011 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-6.2
Price to Revenue0.0 Debt to Equity0.0 EBITDA-409.565 Million
Price to Book Value7.9915 Operating Margin0.0 Enterprise Value3.96 Billion
Current Ratio8.217 EPS Growth-2.546 Quick Ratio8.058
1 Yr BETA 1.1322 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-323.375 Altman Z-Score25.5595 Free Cash Flow to Firm -251.431 Million
View SEC Filings from AVXS instead.

View recent insider trading info

AveXis Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AVXS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVXS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2018-05-15 by NOVARTIS AG
  • 4: filed on 2018-05-15 by WELCH DANIEL G
  • 4: filed on 2018-05-15 by VERWIEL FRANK
  • 4: filed on 2018-05-15 by SMITH LORI J.
  • 4: filed on 2018-05-15 by SIFFERT JOAO MD
  • 4: filed on 2018-05-15 by SESSION R.A. II
  • 4: filed on 2018-05-15 by NOLAN SEAN P.
  • 4: filed on 2018-05-15 by NAGENDRAN SUKUMAR
  • 4: filed on 2018-05-15 by MODI RICK
  • 4: filed on 2018-05-15 by MANNING PAUL B

    • Events (8k)

  • 8-K: filed on 2018-05-15:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-05-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-04-25:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-04-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-03-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-18:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-04:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    NOVARTIS AG

    • 10% Owner
    		 36,816,476 2018-05-15 0

    LITALIEN JAMES J SRVP/CHIEF REG&QUALITY OFFICER

    • Officer
    		 No longer subject to file 2018-05-15 0

    WELCH DANIEL G

    • Director
    		 No longer subject to file 2018-05-15 0

    DONENBERG PHILLIP B. CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2018-05-15 0

    KEARNEY TERRENCE C

    • Director
    		 No longer subject to file 2018-05-15 0

    MANNING PAUL B

    • Director
    • FORMER 10% OWNER
    		 No longer subject to file 2018-05-15 0

    SIFFERT JOAO MD

    • Director
    		 No longer subject to file 2018-05-15 0

    VERWIEL FRANK

    • Director
    		 No longer subject to file 2018-05-15 0

    NOLAN SEAN P. PRESIDENT & CEO

    • Officer
    • Director
    		 No longer subject to file 2018-05-15 0

    KOH BONG Y

    • Director
    		 No longer subject to file 2018-05-15 0

    MODI RICK CHIEF BUSINESS OFFICER

    • Officer
    		 No longer subject to file 2018-05-15 0

    NAGENDRAN SUKUMAR SR. VP & CHIEF MEDICAL OFFICER

    • Officer
    		 No longer subject to file 2018-05-15 0

    KNUDTEN ANDREW F. SRVP/MANUFACTURE&SUPPLY CHAIN

    • Officer
    		 No longer subject to file 2018-05-15 0

    KASPAR BRIAN K. CHIEF SCIENTIFIC OFFICER

    • Officer
    • Director
    		 No longer subject to file 2018-05-15 0

    JOHANNESEN MICHAEL GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2018-05-15 0

    SESSION R.A. II SR. VP, CORP STRATEGY

    • Officer
    		 No longer subject to file 2018-05-15 0

    SMITH LORI J. SVP-CHIEF HUMAN RESOURCE OFF.

    • Officer
    		 No longer subject to file 2018-05-15 0

    DEE THOMAS J. SR. VP & CFO

    • Officer
    		 0 2017-05-10 0

    DEERFIELD PARTNERS, LP

    DEERFIELD INTERNATIONAL MASTER FUND, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 210,000 2016-02-17 0

    MANNING PAUL B

    PBM CAPITAL INVESTMENTS, LLC

    • Director
    • FORMER 10% OWNERFORMER 10% OWNER
    		 1,912,176 2016-02-17 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    • Director
    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 131,911 2016-02-10 0

    FLYNN JAMES E

    DEERFIELD MANAGEMENT CO

    • Director
    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 0 2016-02-10 0

    LEFF JONATHAN S

    • Director
    		 0 2016-02-10 0

    NUECHTERLEIN CAROLE

    • Director
    		 0 2016-02-10 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD PARTNERS, LP

    DEERFIELD INTERNATIONAL MASTER FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • Director
    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 2,236,700 2015-09-03 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments